Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

quantum physics

Bayer looks to leverage AI across the pharma value chain

Dieter Weinand outlines his hopes for applying artificial intelligence

AstraZeneca AZ

AZ pushes back data read-out from MYSTIC lung cancer trial

The delay could further undermine confidence in a positive outcome

- PMLiVE

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

The duo will start a series of clinical trials combining the multiple RTK inhibitor and Keytruda

AstraZeneca AZ

CHMP backs AZ’s Lynparza for ovarian cancer maintenance

Studies show that the drug reduced risk of disease progression

- PMLiVE

Merck buys cancer-killing virus firm Viralytics for $394m

It will acquire the Australian biotech’s lead cancer therapy Cavatek in the process

- PMLiVE

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Bavencio fails a key lung cancer trial

Bristol-Myers Squibb (BMS) building

BMS pens massive $3.6bn deal for Nektar cancer immunotherapy

Nektar’s NKTR-214 to be paired with Opdivo and Yervoy in a host of tumour types

AI Voice Assistants

Battle of the Voice Assistants and Voice Search

At-a-glance crib sheet on how the battle of the voice assistants is shaping up between Amazon, Google, Apple, Microsoft and Samsung.

An agency called Owen

Fujitsu begins two-year medical AI research project

Partners with Kyoto University on R&D-focused work

- PMLiVE

Dr Fiona Marshall heads up MSD’s new UK research facility

She will be based in London and focus on early bioscience discovery

- PMLiVE

Merck chalks up another win for Keytruda in lung cancer

Becomes the first PD-1 inhibitor to improve OS in NSCLC patients when combined with chemo

- PMLiVE

AZ and Merck & Co get FDA breast cancer nod for Lynparza

It becomes the first PARP inhibitor to be approved outside ovarian cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links